FDA and GlobalSubmit Pilot Prototype Software for Loading HL7 Messages into Janus Version 2 Database - Applied Clinical Trials

ADVERTISEMENT

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
See our 2009 Buyers Guide Digital Edition.
Find Pharma Search Engine
FDA and GlobalSubmit Pilot Prototype Software for Loading HL7 Messages into Janus Version 2 Database

Company News Release

Philadelphia, PA—August 18, 2009

GlobalSubmit Inc., a developer of software designed for the review and validation of electronic Common Technical Document (eCTD) global submissions, has launched a project focused on developing a prototype that loads HL7 messages into a Janus Version 2 database and exports those messages in a Study Data Tabulation Model (SDTM) file format.

While the company is close to completing the development of that prototype, it has also extended the model so that it will load and export both SDTM and HL7 files. Recently, GlobalSubmit and the FDA began the actual testing of these solutions by reviewing HL7 Study Design, Study Participation, and Subject Data.

In late July, GlobalSubmit met with the National Center for Toxicological Research (NCTR) at its offices in Jefferson, Arkansas. While there, GlobalSubmit installed the prototype Janus Version 2 database. GlobalSubmit also reviewed the Study Design prototype, which, when in production, will expedite the protocol review process. That prototype runs seamlessly “on top of” the Janus prototype database.  

During the pilot period, the FDA will receive data in a standard HL7 format and load that data into its prototype Janus Version 2 database. In addition to the Janus Version 2 database, FDA will also make use of enhanced analytical, mathematical, visualization and other computational tools and techniques that enable reviewers to search, model, and analyze data to conduct better safety and efficacy analyses.

When asked about the project, Jason Rock, CTO, GlobalSubmit said, “Our vision and the Agency’s vision are closely aligned in that both organizations want to improve the management of all structured scientific data, including standardized clinical study data. When realized, this shared vision will increase transparency for regulated products, leading to safer and more effective drugs being offered in the marketplace.”

ADVERTISEMENT

ADVERTISEMENT

Almac Doubles Capacity at North Carolina Facility
i3 Partners with Acurian to Provide Site Selection Services to Clinical Trial Sponsors
PPD to Acquire BioDuro
Ecron Acunova Launches Direct Operation in Russia
Health Decisions Welcomes KLIXAR into the Agile Clinical Network
FindPharma
Survey
Would you ever consider working as a freelance clinical research professional?
Yes, I'd love to
Yes, but would never do it
No, but may have to
Absolutely not, no stability
Yes, I'd love to
75%
Yes, but would never do it
8%
No, but may have to
17%
Absolutely not, no stability
0%
View Results
Source: Company News Release,
Click here